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Abstract
Background: Cardiovascular disease (CVD) is a group of disorders of the heart and blood vessels, such as coronary heart
disease (CHD), cerebrovascular disease, and peripheral artery disease. CVD is the leading threat to global health, whether measured
by mortality, morbidity, or economic cost. Long-term administration of aspirin, statins, beta-blockers, and angiotensin-converting
enzyme inhibitors or angiotensin-receptor blockers improves survival in patients with stablished coronary heart disease. Nevertheless,
adherence to prescribed medication is poor for long-term drug treatment.
Objective: We aim to assess the relationship between adherences to the four pharmacological groups recommended for secondary
prevention and the clinical outcomes of cardiovascular morbidity and mortality in patients with established CHD according to
the level of adherence to these drugs in a population of incident cases of acute coronary syndrome (ACS).
Methods: Population-based cohort study of patients with a first episode of ACS during 2006-2015 in the Information System
for Research in Primary Care (SIDIAP) database. We will estimate adherence to these drugs. The primary endpoint is a composite
of all-cause mortality, ACS, and ischaemic stroke. Bivariate analyses will be performed estimating odds ratios for categorical
variables and mean differences for continuous variables. Hazard ratios for adherences will be calculated for outcome events using
Cox proportional hazard regression models, and proportionality of hazards assumption will be tested.
Results: We expect to estimate adherence to all four study treatments, the incidence of MACE, and to analyze if this incidence
is associated with the level of drug adherence.
Conclusions: We expect to find that adherent patients have a lower risk of the primary endpoints compared with nonadherent
patients.
Trial Registration: This study protocol was classified as EPA-OD by the AEMPS (IJG-EST-2017-01-2017-01, 07/04/2017)
and registered in the EU PAS register (EUPAS19017, 09/05/2017).
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Introduction
Cardiovascular disease (CVD) is a group of disorders of the
heart and blood vessels, such as coronary heart disease (CHD),
cerebrovascular disease, and peripheral artery disease. CVD is
the leading threat to global health, whether measured by
mortality, morbidity, or economic cost [1]. In 2012, it was the
leading cause of mortality worldwide, accounting for 31% of
an estimated 56 million deaths from all causes. Also, CVD was
responsible for the largest proportion of deaths for
noncommunicable diseases under the age of 70 years, 37% of
16 million deaths [2].
Despite these numbers, the incidence of CVD death has
decreased dramatically over the last four decades due to both
population-level lifestyle changes in diet, smoking, and physical
activity, and the development of effective interventions to treat
individuals. The latter includes invasive procedures and effective
drugs to tackle modifiable CVD risk factors [3].
A number of randomized clinical trials, meta-analyses and
cohort studies have demonstrated that long-term administration
of aspirin, statins, beta-blockers, and angiotensin-converting
enzyme inhibitors (ACEI) or angiotensin-receptor blockers
(ARB) improve survival in high-risk patients, particularly those
with established CVD. Nevertheless, adherence to prescribed
medication is poor for long-term drug treatment in CVD [1,4-6].
Different factors have been described to be related with
long-term nonadherence [1,5-7].
In a recent cohort study conducted by Bansilal et al [4], 4015
patients who had suffered an acute myocardial infarction (AMI)
were categorized according to their drug adherence to statin and
ACEI into three categories: fully adherent (≥80% proportion of
days covered [PDC]), partially adherent (40-79% PDC) or
nonadherent (<40% PDC). Fully adherents had lower rates of
major cardiovascular events (MACE) than partially adherents,
18.9% vs 24.7% (adjusted hazard ratio [HR] 0.81, 95% CI
0.69-0.94) and nonadherents, 18.9% vs 26.3% (HR 0.72, 95%
CI 0.62-0.85).
In the cohort study conducted by Lafeber et al [8], 2706 CHD
patients were included. Of them, 67% were treated with a
combination of aspirin, statin, and at least one blood pressure
(BP)-lowering agent for secondary prevention. After a median
follow-up period of five years, the combination therapy
compared with no combination showed lower rates for all
events: AMI, HR 0.68 (95% CI 0.49-0.96); ischaemic stroke,
HR 0.37 (95% CI 0.16-0.84); vascular mortality, HR 0.53 (95%
CI 0.33-0.85); composite endpoint of the previous events, HR
0.66 (95% CI 0.49-0.88); and all-cause mortality, HR 0.69 (95%
CI 0.49-0.96).
A population-based cohort study performed in Spain assessed
adherence to secondary prevention drugs in a cohort of 7462
patients who survived an acute coronary syndrome (ACS) [6].
Medication adherence was evaluated by determining the PDC
for each therapeutic group (antiplatelet agents, beta-blockers,
ACEI or ARB, and statins) in the nine months following hospital
discharge. Full adherence was defined as PDC75, at least 75%
of days of the follow-up period covered by treatments dispensed.
PDC75 for antiplatelet agents was reached by 5216 (69.9%)
patients, for beta-blockers by 3231 (43.3%) patients, for
ACEI/ARB by 3388 (45.4%) patients, and for statins by 4388
(58.8%). Only 3552 (47.6%) patients reached PDC75 for three
or more therapeutic groups, whereas 1343 (18%) of patients did
not reach PDC75 with any treatment. Some factors found to be
related with nonadherence were older age, female sex, or
copayment of drugs dispensed.
In a meta-analysis of 20 studies [9] in 376,162 patients assessing
adherence to drugs for the primary or secondary prevention of
a CHD event using prescription refill frequency, the estimated
overall adherence to cardiovascular medications was only 57%
(95% CI 50–64) after a median of 24 months, although it was
superior in secondary prevention 66% (95% CI 56–75) than in
primary prevention users (50%, 95% CI 45–56).
A large epidemiological study enrolled 7519 participants with
established CVD from urban and rural communities in countries
at various stages of economic development [10]. Use of
antiplatelet drugs, beta-blockers, ACEI or ARB, and statins was
assessed. Overall, 4421 (58.5%) individuals were not taking
any of the four proven effective drugs, whereas 233 (3.1%) were
taking all four drug types. Individuals recruited in high-income
countries had had a CHD event or stroke a median of 6.0 years
(interquartile range [IQR] 3.0–10.0) before inclusion. Although
medication use increased in line with increase of country
economic status, adherence rates in high-income countries were
sparse too: 62.0% for antiplatelet drugs, 40.0% for beta-blockers,
49.8% for ACEI or ARB and 66.5% for statins.
A meta-analysis of randomised clinical trials assessed adherence
to therapy comparing different dosing regimens in patients with
chronic CVD.[11] The study showed that dosing regimens with
once-daily administration, compared with two or more daily
administrations, were associated with a significant 56% risk
reduction of nonadherence to drug therapy (relative risk 0.44,
95% CI 0.35–0.54).
Due to the improvement of morbidity and mortality found with
the quadruple drug therapy with antiplatelet, beta-blocker, ACEI
or ARB, and statin in patients with established CVD, it is
necessary to assess the long-term adherence to these drugs in
the Catalan population and its relationship with cardiovascular
events and mortality. Our hypothesis is patients with established
CHD who adhere to drug therapy with the four recommended
pharmacological groups have a lower risk of MACE and
all-cause mortality compared with patients who do not adhere
to drug therapy.
The main objective of our study is to assess the relationship
between adherences to the four pharmacological groups
recommended for secondary prevention and the clinical
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outcomes of cardiovascular morbidity and mortality in patients
with established CHD. The outcomes which are included as
components of the composite endpoint are all-cause mortality,
ACS, and ischaemic stroke. The secondary objectives are: 1)
to assess the incidence of the composite endpoint in patients
who are adherent to treatment with all four drugs compared
with patients who are adherent to any combination of three, two
or one drug, or no drug; 2) to assess the relationship between
baseline sociodemographic and clinical characteristics and
adherence to drug therapy; 3) to compare the number of days
on sickness leave due to any cause according to adherence to
drug therapy; 4) to estimate prevalence of use of the four drug
treatments; and 5) to describe the posology prescribed for the
four drug treatments.
Methods
Study design
The study is a population-based retrospective cohort study.
Study Period
Inclusion period was between 2006-2015. The follow-up period
was up to 2016.
Study Population
The study population includes individuals ≥18 years with an
incident diagnosis of ACS during the study period 2006-2015,
with at least two months of follow-up in the Information System
for Research in Primary Care (SIDIAP) [12] after the index
date. The next patients will be excluded: pregnant women on
the index date; patients with a recorded diagnosis of ischaemic
stroke in the six months prior to index date; patients living in a
nursing home on the index date; and patients with Alzheimer’s
disease or other dementias.
Case definition: patient with an incident diagnosis of ACS
registered in CMBD-HA (dataset of diagnoses at hospital
discharge) [13] of the Catalan Health Institute (ICS) within the
period from 2006-2015. Index date definition: date of ACS
episode.
Data Collection and Data Sources
Diagnoses for study inclusion and endpoints will be obtained
from CMBD-HA, which contains diagnoses at hospital discharge
from all ICS hospitals, coded with International Classification
of Diseases, Nineth Revision (ICD-9) [14]; see Table 1.
The rest of the variables will be captured from SIDIAP, which
contains anonymized clinical information of all 279 PHC centres
managed by the ICS in Catalonia (North-East Spain), covering
a population of more than 5.8 million patients (about 80% of
the total of 7.5 million population in Catalonia). The information
contained in SIDIAP is registered by PHC general practitioners
(GP), nurses and administrative staff in ECAP (electronic health
records in ICS): comprehensive sociodemographic information,
health conditions registered as ICD10 codes [15], specialist
referrals, clinical parameters, toxic habits, PHC laboratory test
results, GPs prescriptions and their corresponding pharmacy
invoice data registered as Anatomical, therapeutic, chemical
classification system (ATC) codes [16], date of sickness leave
due to any cause, and date of death. Several reports have shown
that SIDIAP data is useful for epidemiological research [17-25].
SIDIAP is listed under the European Network of Centres for
Pharmacoepidemiology and Pharmacovigilance (ENCePP)
resources database [26].
Sample Size
The sample will be all patients with a first episode of ACS
registered in CMBD-HA of ICS hospitals who meet all inclusion
criteria and none of the exclusion criteria during the study
period. In a previous study on patients with ACS conducted
with SIDIAP database (publication pending) during the period
2009-2011, there were 3415 cases of ACS for all hospitals in
Catalonia. Data from CMBD-HA of ICS hospitals corresponds
approximately to 30% of all hospitals. Taking into account that
our study period is 2006-2015 (10 years), we estimate to find
approximately 3400 cases of ACS meeting inclusion criteria
for our study.
Variables
Exposure Definition
Patients will be classified as “exposed” to the study drugs
(antiplatelet agents, beta-blockers, ACEI or ARB, statins) if
they are prescribed any of them after the episode of ACS (up
to two months after the event). The dose prescribed in ECAP
will be considered the daily dose used for the patient, and the
number of tablets contained in each package will cover the same
number of days (see drugs of study in Table 2).
Table 1. International Classification of Diseases, Nineth Revision (ICD-9) codes for endpoints of study and procedures.
DescriptionICD-9 code
Unstable angina and other forms of acute coronary heart disease411*
Acute myocardial infarction410*
Ischaemic stroke433*, 434*, 435*, 436*, 437*
Coronary angioplasty00.66, 36.03, 36.09, 39.50
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Table 2. Anatomical, therapeutic, chemical classification system (ATC) codes for drugs of interest.
Description of therapeutic groupATC code
Study drugs
Platelet-aggregation inhibitorsB01AC
Beta-blockersC07
Angiotensin-converting enzyme inhibitorsC09A, C09B
Angiotensin-receptor blockersC09C, C09D
StatinsC10AA, C10B
Concomitant drugs
DiureticsC03
Antihypertensive drugsC02
Calcium-channel blockers (dihydropyridines/verapamil, diltiazem)C08CA, C08D
AnticoagulantsB01AA, B01AB, B01AD, B01AE, B01AF, B01AX
Drugs used in diabetes mellitusA10
Other lipid-lowering drugsC10AB, C10AC, C10AD, C10AX
Digoxin and antiarrhythmic drugsC01A, C01B
NitratesC01DA
AntipsychoticsN05A
Non-steroidal anti-inflammatory drugsM01A, N02BA, N02BB
Adherence Definition
To estimate medication adherence, we will calculate the PDC
for all four study treatments during eight months of follow-up
after the index date. The PDC calculation is based on the
packages dispensed and days of supply for each package,
considering that the number of tablets contained in one package
covers the treatment necessary for 28 or 30 days, depending on
the drug. The information will be obtained from the pharmacy
invoice data. For the PDC calculation, the numerator is the
number of packages dispensed (invoice register) during the first
8 months of follow-up, and the denominator is the period of 8
months, which is the period for the adherence measure. Based
on the PDC, patient adherence to each study drug is usually
classified into one of two categories using the standard threshold
of 75% (≥75%: adherent, <75%: nonadherent) [6,9]. PDC=75%
accounts for six packages (each one including one month of
drug treatment) dispensed during eight months. We define
adherent patients as those who have received at least six
packages during the first eight months after the event. Finally,
according to adherence to all four study drugs, patients will be
classified as adherent if they get the refill for all study drugs:
PDC antiplatelet ≥75% + PDC beta-blockers ≥75% + PDC
ACEI/ARB ≥75% + PDC statin ≥75%.
Study Endpoints
ICD-9 codes for primary and secondary endpoints can be seen
in Table 1. They will be captured from CMBD-HA database.
Primary Endpoint
The primary endpoint will be a composite endpoint of all-cause
mortality, ACS and ischaemic stroke. From the index date (first
episode of ACS), patients will be followed up to the end of
follow-up or until a new diagnosis of any of the endpoints stated
above. Patients who experience more than one endpoint during
the study follow-up will be censored upon the first event of
interest. Patients who do not experience any of the clinical
events included in the composite endpoint during the follow-up
will be censored at the last date of follow-up.
Secondary Endpoints
The secondary endpoints will be AMI, unstable angina,
ischaemic stroke, all-cause mortality, overall number of days
on sickness leave due to any cause and due to CVD events,
prevalence of use of the four pharmacological groups of interest,
posology of the four pharmacological groups of interest.
Other Variables
All the following variables will be considered as potential
confounders or effect modifiers in the association between
adherence to the drug therapy and risk of the composite
endpoint. They will be captured from SIDIAP database:
Patient Baseline Characteristics
All sociodemographic characteristics will be measured on the
index date: index year, number of visits to PHC, age, sex,
MEDEA index (socioeconomic deprivation index) [27], smoking
status, alcohol intake, height, weight, Body Mass Index (BMI);
the information comes primarily from a codified variable. If the
patient has no information, it is calculated from height and
weight and physical activity.
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Table 3. ICD-10 codes for comorbidities of interest or diseases for exclusion
DescriptionICD-10 code
Coronary heart diseaseI24*, I25*
Ischaemic strokeI63*, I65*, I66*, I67.2, I67.8
Transient cerebral ischaemic attackG45
Peripheral vascular diseaseI70*, I73*, I74*
DyslipidaemiaE78*
HypertensionI10*, I15*
Diabetes mellitusE10*, E11*
Atrial fibrillationI48
Heart failureI50*
MalignanciesC00*-C97*
Chronic obstructive pulmonary diseaseJ40*-J44*
DepressionF30*-F39*
Arthritis (osteoarthritis or rheumatoid arthritis)M05*, M06*, M15*-M19*
OsteoporosisM80*, M81*
Chronic kidney diseaseN18*
HIVB20*-B24*
Alzheimer’s disease, other dementiasG30*, G31*
Comorbidities and Clinical Parameters
They will be measured closest to the index date: type of
cardiovascular event at index date (AMI and unstable angina
and other forms of ACS captured from CMBD-HA), presence
of coronary angioplasty implant after the event (data source
CMBD-HA), cholesterol and other lipid parameters (low density
lipoprotein-cholesterol, high density lipoprotein-cholesterol,
total-cholesterol, and triglycerides), blood pressure measured
(systolic and diastolic blood pressure), glycated hemoglobin,
glomerular filtration rate, serum creatinine, specific comorbid
conditions (see ICD-10 codes in Table 3), Charlson comorbidity
index [28,29].
Concomitant Drug Use
For all patients, baseline information on other medications for
CVD prescribed throughout follow-up will be captured from
the pharmacy invoice (see ATC codes for drugs in Table 2).
Statistical analysis
Demographic and baseline characteristics of the participants
will be described using frequencies and percentages for
categorical variables and mean, standard deviation or median
and interquartile range for continuous variables, as appropriate.
Bivariate analyses will be performed estimating odds ratios for
categorical variables and mean differences for continuous
variables as well as their respective 95% CI. Multiple
imputations by chained equations will be used to replace
baseline missing values. Case-complete and imputed data results
will be compared as a sensitivity analysis. The raw and adjusted
HRs for adherences will be calculated for outcome events using
Cox proportional hazard regression models, and proportionality
of hazards assumption will be tested. Association analyses
between adherence to study drugs, incidence of the endpoints
or sick leave, and drug therapy (objectives 1, 2 and 3) will be
analysed by means of generalized linear models. Objectives 4
and 5 are descriptive and they will be described using
frequencies and percentages as appropriate.
Ethical Aspects and Data Confidentiality
The present study follows national and international regulations:
Declaration of Helsinki Ethical Principles for Medical Research
Involving Human Subjects and Good Research Practice
principles and guidelines. The study protocol has been approved
by Institut Universitari d’Investigació en Atenció Primària
(IDIAP) Jordi Gol Clinical Research Ethics Committee, the
reference institution for research in PHC of the ICS, at May 3,
2017. Regarding the data contained in the databases and
according to Spanish legislation about confidentiality and data
protection (Ley Orgánica 15/1999 de 13 de diciembre de
Protección de Datos de Carácter Personal), data included in
SIDIAP are always anonymized. Thus, it is not necessary to
ask for informed consent from the participants.
Results
We expect to estimate adherence to all four study treatments,
the incidence of MACE, and to analyze if this incidence is
associated with the level of drug adherence. Adherence to drug
treatment has shown better results in terms of risk reduction of
MACE, so we expect to find that adherent patients have a lower
risk of the primary endpoints in comparison with nonadherent
patients.
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Discussion
We expect to find that adherent patients have a lower risk of
the primary endpoints in comparison with nonadherent patients.
Selection bias is a common limitation in observational studies.
In order to avoid this bias, where the population with missing
data differs from those with complete data, missing values for
continuous variables will be imputed instead of excluding
records with missing data.
Another limitation is the presence of potential confounders. To
minimize confounders’ effects, Cox regression models adjusted
for sociodemographic characteristics and for possible
confounders and predictive factors will be used.
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AEMPS: agencia Española de medicamentos y productos sanitarios
AMI: acute myocardial infarction
ARB: angiotensin-receptor blockers
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BMI: body mass index
BP: blood pressure
CHD: coronary heart disease
CMBD-HA: conjunt mínim bàsic de dades a d’hospitalizació d’aguts (minimum dataset of
CVD: cardiovascular disease
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PDC: proportion of days covered
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